

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - NCAB asks for help from administration as NCI deals with deluge of grant applications
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Raja Flores says oncology is loose with staging jargon, and now “it’s confusing my patients.”
















